<DOC>
	<DOC>NCT00041795</DOC>
	<brief_summary>This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.</brief_summary>
	<brief_title>Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<criteria>Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy. Sensory or motor neuropathy must be &gt;/= grade 2 per Common Toxicity Criteria at baseline. In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable. Patient must have normal hematological cell counts. Patient must have a life expectancy of &gt;/= 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2002</verification_date>
</DOC>